KURA vs IMMX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KURA · Kura Oncology$7.27 ▲ 6.91%
IMMX · Immix Biopharma$8.06 ▲ 11.94%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KURA -29.6%
- IMMX +148.8%
Head to head
| Metric | KURA | IMMX |
|---|---|---|
| Price | $7.27 | $8.06 |
| Change today | ▲ 6.91% | ▲ 11.94% |
| Market cap | $646.74M | $669.62M |
| Return, 3 months | -26.2% | -20.4% |
| Return, year to date | -30.0% | +54.1% |
| Return, 1 year | -26.3% | +155.9% |
| P/E (TTM) | – | – |
| P/B | 13.4 | 2.9 |
| P/E percentile vs own 5y | 88th | 21st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +36.5% | – |
| Net profit growth (YoY) | -3.3% | -74.5% |
| Gross margin | 99.3% | – |
| Operating margin | -411.9% | – |
| Net margin | -384.3% | – |
| Return on equity | -167.7% | -34.2% |
| Analyst target vs. price | +278.3% | +214.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 29 | 43 |
| 30-day volatility | 96.0% | 78.4% |
| Max drawdown, 1 year | -50.0% | -50.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IMMX is the largest of the group by market value.
- IMMX has returned the most over the past year.
- IMMX has been the calmest stock over the last 30 days.